Send to

Choose Destination
Immune Netw. 2018 Feb 22;18(1):e12. doi: 10.4110/in.2018.18.e12. eCollection 2018 Feb.

Ectopically Expressed Membrane-bound Form of IL-9 Exerts Immune-stimulatory Effect on CT26 Colon Carcinoma Cells.

Author information

Department of Biochemistry, College of Natural Sciences, Chungnam National University, Daejeon 34134, Korea.
Institute of Biotechnology, Chungnam National University, Daejeon 34134, Korea.


IL-9 is a known T cell growth factor with pleiotropic immunological functions, especially in parasite infection and colitis. However, its role in tumor growth is controversial. In this study, we generated tumor clones expressing the membrane-bound form of IL-9 (MB-IL-9) and investigated their influences on immune system. MB-IL-9 tumor clones showed reduced tumorigenicity but shortened survival accompanied with severe body weight loss in mice. MB-IL-9 expression on tumor cells had no effect on cell proliferation or major histocompatibility complex class I expression in vitro. MB-IL-9 tumor clones were effective in amplifying CD4+ and CD8+ T cells and increasing cytotoxic activity against CT26 cells in vivo. We also observed a prominent reduction in body weights and survival period of mice injected intraperitoneally with MB-IL-9 clones compared with control groups. Ratios of IL-17 to interferon (IFN)-γ in serum level and tumor mass were higher in mice implanted with MB-IL-9 tumor clones than those observed in mice implanted with control cells. These results indicate that the ectopic expression of the MB-IL-9 on tumor cells exerts an immune-stimulatory effect with toxicity. To exploit its benefits as a tumor vaccine, a strategy to control the toxicity of MB-IL-9 tumor clones should be developed.


Cancer vaccine; Colon carcinoma; Interleukin-9; Membrane-bound; Toxicity

Conflict of interest statement

Conflict of Interest: The authors declare no potential conflicts of interest.

Supplemental Content

Full text links

Icon for Korean Association of Immunologists Icon for PubMed Central
Loading ...
Support Center